journal
MENU ▼
Read by QxMD icon Read
search

Cancer Discovery

journal
https://www.readbyqxmd.com/read/29025772/impaired-hla-class-i-antigen-processing-and-presentation-as-a-mechanism-of-acquired-resistance-to-immune-checkpoint-inhibitors-in-lung-cancer
#1
Scott Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar, Ryan Sowell, Anna Wurtz, Weilai Dong, Guoping Cai, Mary Ann Melnick, Victor Y Du, Joseph Schlessinger, Sarah B Goldberg, Anne Chiang, Miguel F Sanmamed, Ignacio Melero, Jackeline Agorreta, Luis M Montuenga, Richard Lifton, Soldano Ferrone, Paula Kavathas, David L Rimm, Susan M Kaech, Kurt A Schalper, Roy S Herbst, Katerina Politi
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell surface HLA class I expression in the tumor and a matched patient-derived xenograft (PDX)...
October 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29025771/endothelial-activation-and-blood-brain-barrier-disruption-in-neurotoxicity-after-adoptive-immunotherapy-with-cd19-car-t-cells
#2
Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F Gonzalez-Cuyar, Cecilia Yeung, W Conrad Liles, Mark Wurfel, Jose A Lopez, Junmei Chen, Dominic Chung, Susanna Harju-Baker, Tahsin Özpolat, Kathleen R Fink, Stanley R Riddell, David G Maloney, Cameron J Turtle
Lymphodepletion chemotherapy followed by infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells can be complicated by neurologic adverse events (AE) in patients with refractory B-cell malignancies. In 133 adults treated with CD19 CAR-T cells, we found that acute lymphoblastic leukemia, high CD19(+) cells in bone marrow, high CAR-T cell dose, cytokine release syndrome, and preexisting neurologic comorbidities were associated with increased risk of neurologic AEs. Patients with severe neurotoxicity demonstrated evidence of endothelial activation, including disseminated intravascular coagulation, capillary leak, and increased blood-brain barrier (BBB) permeability...
October 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29021134/nih-funds-pediatric-data-resource-center
#3
(no author information available yet)
Children's Hospital of Philadelphia will lead a collaborative effort-funded with $14.8 million from the NIH-to pool genomic and phenotypic data from tens of thousands of patients to study the causes of pediatric cancer and structural birth defects.
October 11, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29017995/germline-testing-could-help-more-patients
#4
(no author information available yet)
In addition to tumor sequencing for targetable somatic alterations, patients with cancer may benefit from concurrent germline analysis, which increases the discovery of clinically actionable mutations, according to a recent study.
October 10, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28993313/checkpoint-inhibitors-spur-changes-in-trial-design
#5
(no author information available yet)
Given the success of checkpoint inhibitors and the desire to test them in combination with other immunotherapies and targeted therapies, hundreds of clinical trials have been launched. To most efficiently study these agents, researchers and the FDA are exploring the use of novel endpoints, the use of new preclinical models, and adaptive trial designs. However, the cost and demands associated with the conduct of increasingly sophisticated early-phase clinical trials are putting smaller companies and some academic medical centers at a disadvantage...
October 9, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28986369/mettl3-increases-m-6-a-to-block-differentiation-and-promote-leukemogenesis
#6
(no author information available yet)
METTL3 is upregulated in acute myeloid leukemia compared with other tumors and normal HSPCs.
October 6, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28986368/chromosome-1q21-3-amplification-is-linked-to-breast-cancer-recurrence
#7
(no author information available yet)
The 1q21.3 amplification can be detected in cfDNA from most patients with recurrent breast cancer.
October 6, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28986367/inhibition-of-p300-cbp-suppresses-castration-resistant-prostate-cancer
#8
(no author information available yet)
A virtual ligand screen led to generation of A-485, a potent selective p300/CBP catalytic inhibitor.
October 6, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28986366/pak-signaling-promotes-acquired-resistance-to-braf-and-mek-inhibitors
#9
(no author information available yet)
PAK signaling drives resistance to BRAF inhibition and dual BRAF/MEK inhibition via distinct mechanisms.
October 6, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28986365/the-splicing-regulator-prmt5-is-critical-for-glioblastoma-proliferation
#10
(no author information available yet)
PRMT5 regulates the splicing of detained introns in proliferation-associated genes in GBM.
October 6, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28982661/fda-approves-first-biosimilar-to-treat-cancer
#11
(no author information available yet)
The FDA approved the VEGF inhibitor bevacizumab-awwb for the treatment of five types of cancer: nonsquamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, renal cell carcinoma, and glioblastoma. A biosimilar to bevacizumab, the agent is the first such drug approved for the treatment of cancer.
October 5, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28978559/fda-oks-abemaciclib-for-er-her2-breast-cancer
#12
(no author information available yet)
The FDA has approved abemaciclib for women with advanced or metastatic ER-positive, HER2-negative breast cancer whose disease has progressed on endocrine therapy. This is the third CDK4/6 inhibitor to get the agency's go-ahead in 2.5 years.
October 4, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28978558/targeting-angiogenesis-in-bladder-cancer
#13
(no author information available yet)
Findings from the phase III RANGE study indicate that adding ramucirumab to docetaxel may improve progression-free survival for patients with advanced or metastatic urothelial carcinoma whose disease is refractory to platinum chemotherapy.
October 4, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28978557/nivolumab-approved-for-liver-cancer
#14
(no author information available yet)
The FDA granted accelerated approval to nivolumab for second-line treatment of advanced hepatocellular carcinoma, making it just the third drug on the market for the disease. The PD-1 inhibitor is approved for patients who cannot tolerate sorafenib and those whose disease progressed despite treatment with the multikinase inhibitor.
October 4, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28978556/genomic-heterogeneity-as-a-barrier-to-precision-medicine-in-gastroesophageal-adenocarcinoma
#15
Eirini Pectasides, Matthew D Stachler, Sarah Derks, Yang Liu, Steven Maron, Mirazul Islam, Lindsay Alpert, Heewon Kwak, Hedy Kindler, Blase Polite, Manish R Sharma, Kenisha Allen, Emily O'Day, Samantha Lomnicki, Melissa Maranto, Rajani Kanteti, Carrie Fitzpatrick, Christopher Weber, Namrata Setia, Shu-Yuan Xiao, John Hart, Rebecca Nagy, Kyoung-Mee Kim, Min-Gew Choi, Byung Hoon Min, Katie S Nason, Lea O'Keefe, Masayuki Watanabe, Hideo Baba, Rick Lanman, Agoston T Agoston, David J Oh, Andrew Dunford, Aaron R Thorner, Matthew D Ducar, Bruce M Wollison, Haley A Coleman, Yuan Ji, Mitchell C Posner, Kevin K Roggin, Kiran Turaga, Paul Chang, Kyle Hogarth, Uzma Siddiqui, Andres Gelrud, Gavin Ha, Samuel S Freeman, Justin Rhoades, Sarah Reed, Greg Gydush, Denisse Rotem, Jon Davison, Yu Imamura, Viktor Adalsteinsson, Jeeyun Lee, Adam J Bass, Daniel V Catenacci
Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies, even when guided by genomic biomarkers, have had limited efficacy. A potential reason for the failure of such therapies is that genomic profiling results could commonly differ between the primary and metastatic tumor. To evaluate genomic heterogeneity, we sequenced paired primary GEA and synchronous metastatic lesions across multiple cohorts, finding extensive differences in genomic alterations, including discrepancies in potentially clinically relevant alterations...
October 4, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28974511/tox-regulates-growth-dna-repair-and-genomic-instability-in-t-cell-acute-lymphoblastic-leukemia
#16
Riadh Lobbardi, Jordan Pinder, Barbara Martinez-Pastor, Marina Theodorou, Jessica S Blackburn, Brian J Abraham, Yuka Namiki, Marc Mansour, Nouran S Abdelfattah, Aleksey Molodtsov, Gabriela Alexe, Debra Toiber, Manon de Waard, Esha Jain, Myriam Boukhali, Mattia Lion, Deepak Bhere, Khalid Shah, Alejandro Gutierrez, Kimberly Stegmaier, Lewis B Silverman, Ruslan I Sadreyev, John M Asara, Marjorie A Oettinger, Wilhelm Haas, A Thomas Look, Richard A Young, Raul Mostoslavsky, Graham Dellaire, David M Langenau
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive malignancy of thymocytes. Using a transgenic screen in zebrafish, thymocyte selection-associated high mobility box protein (TOX) was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the initiating pool of transformed clones and elevating genomic instability. TOX is highly expressed in a majority of human T-ALL and is required for proliferation and continued xenograft growth in mice. Using a wide array of functional analyses, we uncovered that TOX binds directly to KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit Non-Homologous End Joining repair (NHEJ)...
October 3, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28963359/asf1a-facilitates-dna-double-strand-break-repair-by-nhej
#17
(no author information available yet)
ASF1A promotes NHEJ over homologous recombination for DNA double-strand break (DSB) repair.
September 29, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28963358/tigecycline-may-selectively-target-leukemic-stem-cells-in-cml
#18
(no author information available yet)
Tigecycline inhibits mitochondrial oxidative phosphorylation to target leukemic stem cells (LSC).
September 29, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28963357/durvalumab-promising-for-nsclc
#19
(no author information available yet)
The PD-L1 inhibitor durvalumab increases progression-free survival and objective response rate in patients with inoperable and locally advanced stage III non-small cell lung cancer, according to interim results of a phase III trial. The benefit was great enough that the drug could become the standard of care in the United States for these patients.
September 29, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28963356/pparg-activated-bladder-cancer-cells-exhibit-a-pparg-dependency
#20
(no author information available yet)
PPARG-selective inverse agonists can suppress proliferation in PPARG-activated bladder cancer cells.
September 29, 2017: Cancer Discovery
journal
journal
43599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"